The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) 
The myeloproliferative neoplasms

According to the 2008 classification system for haematologic malignancies from the World Health Organization (WHO) the category of myeloproliferative neoplasms (MPNs) includes chronic myelogenous leukaemia (CML, which is marked by the t(9;22)(q34;q11) translocation-BCR/ABL rearrangement), polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF), mastocytosis, chronic eosinophilic leukaemia not otherwise specified (CEL-NOS), chronic neutrophilic leukaemia (CNL) and 'MPN, unclassifiable' [1]. In this review, we will focus only on the so-called 'classic' MPNs, that is PV, ET and PMF, with reference to other MPNs if appropriate. These disorders, whose original identification is credited to W. Dameshek in 1951
, share a number of common features [3] that include: the origin in a multi-potent haematopoietic stem cell; an expanded pool of mature cells and precursors with preserved cellular maturation; discrete overlap in the clinical phenotype, and the possibility to transform each into the other or to evolve to acute myeloid leukaemia (AML) [4] . A revision [5] [6] [7] [8] [9] or MPL (MPLW515L/K) [10] and of JAK2 exon 12 mutations [11] , which have rapidly improved knowledge on pathogenetic aspects of the diseases and simplified the diagnostic approach. Several recent reviews on these issues have been published [12] [13] [14] [15] [16] .
PV and ET are relatively indolent disorders [17] [20, 24, 25] [27] [28] [29] . However, the safety of HU as concerns the risk of transformation to acute leukaemia is still an unsettled issue [16, 23] [6, 8, 9] . Additional complex mutations, deletions or insertions have been detected in exon 12 of JAK2 and are usually associated with clinical features typical of a JAK2V617F-negative PV or idiopathic erythrocytosis [11, 51] . Finally, somatic mutations involving codon 515 of MPL [10, 52] [66, 67] , or other key molecules involved in the regulation of gene expression, such as micro-ribonucleic acids (microRNAs) [68] (Fig. 1 [69, 70] , are all common findings in human cancer cells [69] [70] [71] . Reduced global methylation in cancer cells is mainly because hypomethylation of DNA repetitive sequences, coding regions and introns, particularly in areas of the genome characterized by a low content of coding genes, and increases further during cancer progression [72] . Mitotic recombination and chromosomal rearrangements can be facilitated by global DNA hypomethylation [73] [77] . [78] . [79] [87] . However, the fine mechanisms that tune the transcriptional expression of microRNAs are still largely unknown, and may depend on the binding of transcription factors to promoter [88, 89] There is a single report of vorinostat in a patient with a JAK2V617F-positive post-essential thrombocythaemia myelofibrosis who showed improvement in transfusion-dependent anaemia and thrombocytopenia [161] . Modest improvement of anaemia and reduction of transfusional support was also serendipitously observed in a patient with PMF who had received valproic acid for epilepsy prophylaxis [162] .
; in addition, low-dose aspirin is recommended in all PV patients independent of risk category [26] as well as in most patients with ET. The most commonly used cytoreductive agent is hydroxyurea (HU) because of its proven effectiveness in reducing life-threatening cardiovascular events
The mechanistic relevance of gene promoter hypermethylation in genes that do not apparently function as tumour-suppressor genes is a matter of discussion, but it is very likely that these might contribute to the phenotypic diversity of cancer; for example, promoter hypermethylation-induced silencing of tissue inhibitor of metalloproteinases-3 (TIMP-3), which encodes for a protease inhibitor, may result in facilitation of tumour cell dissemination
Hypermethylation of CpG islands in gene promoter regions is often associated with specific modification of histones; however, in some instances gene silencing in association with modified histone profile has been observed even in the absence of CpG island hypermethylation. As a matter of fact, differential chemical modifications of histone tail, that is acetylation and methylation, can affect not only DNA replication and DNA repair, but also gene transcription. Acetylation of histones is accomplished by the competing activities of histone acetyl transferase (HAT) and histone deacetylases (HDAC). Acetylated histones have a reduced interaction with the negatively charged DNA, because of lowered positive charge of lysine residue in the presence of acetyl group, and on turn this facilitates the interaction of transcription factors to consensus target sequences on gene promoter
Drugs for epigenetic therapy
Drugs acting on epigenetic control of gene expression fall into two broad categories: inhibitors of methyltransferases and histone deacetylase (HDAC) inhibitors (listed in
Conclusions
In summary, although preliminary and sometimes conflicting, results of available studies support abnormal epigenetic gene regulation in MPN cells, particularly in PMF [163] , as a contributing mechanism to the pathophysiology of these disorders, and maintain that epigenetics could represent a clinically relevant therapeutic target [163] . Results [164] , and re-activation of silenced gene following decitabine was shown able to overcome resistance both in vitro and in preclinical models [165, 166] ; results of a recent dosefinding trial of decitabine with carboplatin in solid tumours hold much clinical promise. Therefore, one could imagine the opportunity to associate epigenetic therapy either with cytotoxic drugs (hydroxyurea) or with the novel, specific JAK2 inhibitors [163, 167] . The coming years will surely witness great interest and efforts in developing effective, targeted therapy against the longneglected MPNs.
